Projected Users and Market Size Evolution Numerous analysts have published projections on the future use of GLP-1RAs, with all forecasting demand to grow significantly, driven by a combination of factors that include: Increasing Prevalence of Obesity: The number of people living with obesity (BMI of over 30) has tripled since 1975 to c.760m people in 2020
Hernandez Munoz G, Pluchino S
NAD+, Epithalon, Glutathione and SS-31 are not controlled drugs under the Misuse of Drugs Act 1971 and may be supplied in the UK for laboratory research use only
Over time, this may help reduce the appearance of dark spots and uneven patches, leading to a more even-looking complexion
L-Carnitine helps with waste matter disposal too
Measurable weight loss typically becomes apparent at 812 weeks with consistent use and dietary awareness